AXQ Capital LP Sells 92,755 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• AXQ Capital LP cut its Roivant Sciences stake by 70% in the second quarter, selling 92,755 shares and retaining 39,712 shares valued at approximately $1.4 million.
• Institutional investors own 64.76% of ROIV, while insiders sold more than 3.05 million shares worth $107.3 million over the past 90 days, including substantial sales by CEO Eric Venker and insider Mayukh Sukhatme.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus and a $35.14 average price target. Roivant’s latest quarterly loss was narrower than expected, though revenue missed estimates.

AXQ Capital LP trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 70.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,712 shares of the company's stock after selling 92,755 shares during the quarter. AXQ Capital LP's holdings in Roivant Sciences were worth $1,405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of ROIV. SBI Securities Co. Ltd. increased its stake in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences in the fourth quarter valued at about $47,000. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock worth $59,000 after purchasing an additional 2,665 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the transaction, the insider directly owned 18,630,739 shares of the company's stock, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055,913 shares of company stock worth $107,261,258 in the last 90 days. 8.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ROIV shares. Guggenheim upped their price objective on Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Bank of America restated a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. Finally, HC Wainwright restated a "buy" rating and issued a $41.00 target price on shares of Roivant Sciences in a research note on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Roivant Sciences Stock Up 1.5%

Shares of Roivant Sciences stock opened at $34.93 on Friday. Roivant Sciences Ltd. has a twelve month low of $12.54 and a twelve month high of $37.97. The business has a 50-day moving average price of $35.30 and a 200-day moving average price of $31.17. The firm has a market cap of $25.23 billion, a price-to-earnings ratio of -65.91 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. On average, equities analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source